PHARMACOECONOMICS ANALYSIS OF TREATMENT OF METASTATIC COLORECTAL CANCER WITH BEVACIZUMAB IN BRAZIL

被引：0
|
作者：
Tonon, L. M. [1 ]
Secoli, S. R. [2 ]
机构：
[1] Hosp Sirio Libanes, Sao Paulo, Brazil
[2] Univ Fed Sao Paulo, Sao Paulo, Brazil
来源：
VALUE IN HEALTH | 2009年 / 12卷 / 07期
关键词：
D O I：
10.1016/S1098-3015(10)75350-X
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A497 / A497
页数：1
相关论文
共 50 条
  • [41] Bevacizumab plus chemotherapy as salvage treatment in chemorefractory patients with metastatic colorectal cancer: A retrospective analysis.
    Prenen, H.
    Geva, R.
    Piessevaux, H.
    Tejpar, S.
    Verslype, C.
    Vannoote, J.
    Mortier, L.
    Van Cutsem, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [42] Capecitabine and bevacizumab (CB) maintenance treatment in metastatic colorectal cancer (mCRC): A cost-effectiveness analysis
    Franken, M.
    Van Rooijen, E.
    Van Tinteren, H.
    May, A.
    Mol, L.
    Ten Tije, A.
    Creemers, G. J.
    Van der Velden, A.
    Van der Torren, A.
    Uyl-de Groot, C.
    Punt, C.
    Koopman, M.
    Van Oijen, M.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S370 - S370
  • [43] Treatment beyond progression in metastatic colorectal cancer: to double or not to double the dose of bevacizumab?
    Bochis, Ovidiu-Vasile
    Vlad, Catalin
    Cainap, Calin
    Achimas-Cadariu, Patriciu
    Sur, Daniel
    Havasi, Andrei
    Vidrean, Andreea
    Muresan, Alexandra
    Piciu, Andra
    Bota, Madalina
    Constantin, Anne-Marie
    Tat, Tiberiu
    Maniu, Dana
    Crisan, Ovidiu
    Cioban, Cosmin Vasile
    Balacescu, Ovidiu
    Coza, Ovidiu
    Balacescu, Loredana
    Marta, Monica Mihaela
    Cainap, Simona
    JOURNAL OF BUON, 2020, 25 (02): : 875 - 883
  • [44] Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer
    Tappenden, P.
    Jones, R.
    Paisley, S.
    Carroll, C.
    HEALTH TECHNOLOGY ASSESSMENT, 2007, 11 (12) : 1 - +
  • [45] Bevacizumab plus chemotherapy as salvage treatment in chemorefractory patients with metastatic colorectal cancer
    Geva, Ravit
    Vecchione, Loredana
    Tejpar, Sabine
    Piessevaux, Hubert
    Van Cutsem, Eric
    Prenen, Hans
    ONCOTARGETS AND THERAPY, 2013, 6 : 53 - 58
  • [46] Bevacizumab Treatment for Metastatic Colorectal Cancer in Real-World Clinical Practice
    Dinu, Ioana Mihaela
    Mihaila, Mariana
    Diculescu, Mircea Mihai
    Croitoru, Vlad Mihai
    Turcu-Stiolica, Adina
    Bogdan, Diana
    Miron, Monica Ionela
    Lungulescu, Cristian Virgil
    Alexandrescu, Sorin Tiberiu
    Dumitrascu, Traian
    Buica, Florina
    Luca, Ioana Niculina
    Lungulescu, Cristina
    Negulescu, Madalina Cristina
    Gramaticu, Iulia Magdalena
    Cazacu, Irina Mihaela
    Croitoru, Adina Emilia
    MEDICINA-LITHUANIA, 2023, 59 (02):
  • [47] Bevacizumab as a second- or later-line of treatment for metastatic colorectal cancer
    Park, Lee Chun
    Lee, Ho Sup
    Shin, Seong Hoon
    Park, Seun Ja
    Park, Moo In
    Oh, Sung Yong
    Kwon, Hyuk Chan
    Baek, Jin Ho
    Choi, Young Jin
    Kang, Myoung Joo
    Kim, Yang Soo
    WORLD JOURNAL OF GASTROENTEROLOGY, 2012, 18 (10) : 1104 - 1109
  • [48] Role of the Antiangiogenic Agent Bevacizumab in the Treatment of Elderly Patients with Metastatic Colorectal Cancer
    Maria Di Bartolomeo
    Filippo Pietrantonio
    Antonia Martinetti
    Roberto Buzzoni
    Arpine Gevorgyan
    Emilio Bajetta
    Drugs & Aging, 2011, 28 : 83 - 91
  • [49] A phase II study of oxaliplatin, capecitabine and bevacizumab in the treatment of metastatic colorectal cancer
    Hurwitz, H
    Fernando, N
    Yu, DH
    Morse, M
    Blobe, G
    Gockerman, J
    Odogwu, L
    Mahon, M
    Truax, R
    Franklin, A
    ANNALS OF ONCOLOGY, 2005, 16 : 285 - 285
  • [50] Bevacizumab in the treatment of metastatic colorectal cancer: Safety profile and management of adverse events
    Hurwitz, Herbert
    Saini, Shermini
    SEMINARS IN ONCOLOGY, 2006, 33 (05) : S26 - S34
12345